血清磷脂酰肌醇蛋白聚糖3在肝癌临床诊断中的应用价值

用酶链免疫吸附试验（ELISA）测定60例原发性肝细胞癌（HCC）患者，30例肝内胆管癌（ICC）患者，30例乙肝后肝硬化（LC）患者，30例转移性肝癌（MCA）患者，30例健康者血清中磷脂酰肌醇蛋白聚糖3（GPC3）蛋白的含量。采用化学发光法检测血清甲胎蛋白（AFP）的含量。 HCC组患者血清GPC3蛋白、AFP含量均显著高于其他组，差异有统计学意义（ P＜0.05），当以3.5μg/L为诊断界值时，GPC3对HCC的敏感性和特异性分别为83.3％和76.7％。 AFP联合GPC3后能将HCC的检出率由73.3％提高到88.3％。血清GPC3的浓度与患者HBV感染情况以及肿瘤大小有关，而与患者年龄、性别、肝功能、肿瘤数目以及门脉癌栓无关。血清GPC3对HCC的诊断有一定的敏感性和特异性，联合AFP检测可以提高HCC的检出率，具有临床应用价值。

Clinical value of serum glypican 3 in the diagnosis of hepatocellular carcinoma

Five groups were assigned to include intrahepatic cholangiocarcinoma （ ICC, n=30 ） , liver cirrhosis （LC,n=30）,metastatic carcinoma （MCA,n=30） and 30 healthy subjects.The serum level of GPC3 was measured by a sandwich method of enzyme-linked immunosorbent assay （ ELISA ） and alpha-fetoprotein （AFP） by microparticle enzyme immunoassay （MEIA）.The serum levels of GPC3 and AFP were significantly higher than those of other groups （P＆lt;0.05）.At a cut-off value of 3.5μg/L,the sensitivity and specificity of GPC3 in the diagnosis of HCC was 83.3%and 76.7%respectively.The sensitivity of combined measurement of GPC3 and AFP was better than GPC3 or AFP alone.Detectable GPC3 was significantly correlated with the presence of viral hepatitis markers and tumor size.However there was no obvious difference in tumor thrombi in portal vein （ PVTT）, tumor number, age, gender or hepatic function of HCC.Thus,as a sensitive serum diagnostic marker for HCC ,GPC3 may be a good supplement to AFP in differentiating HCC from non-malignant chronic liver diseases and other liver cancers.